Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

(2022) Roos S.G. Sablerolles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Homologous and Heterologous Covid-19 Booster Vaccinations

(2022) Robert L. Atmar et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant

(2022) Xin Zhao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients

(2022) Corine H. GeurtsvanKessel et al.   Science Immunology

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

(2021) Merryn Voysey et al.   LANCET

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

(2021) Denis Y Logunov et al.   LANCET

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

(2021) Shilong Yang et al.   LANCET INFECTIOUS DISEASES

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

(2021) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

(2021) Andreas Greinacher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021

(2021) Jessica R. MacNeil et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Considerations in boosting COVID-19 vaccine immune responses

(2021) Philip R Krause et al.   LANCET

Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern

(2021) Jingwen Ai et al.   CELL RESEARCH

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

(2021) Scott A Halperin et al.   LANCET

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

(2021) Sara Y Tartof et al.   LANCET

Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

(2021) Arabella S V Stuart et al.   LANCET

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

(2021) Shuo Feng et al.   NATURE MEDICINE

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021

(2021) Barbara A. Cohn et al.   SCIENCE

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

(2020) Feng-Cai Zhu et al.   LANCET

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

(2020) Denis Y Logunov et al.   LANCET